## Clinical Context This patient has a BRCA1 germline mutation with early-onset bilateral breast cancer and a strong family history of BRCA-associated malignancies (breast and ovarian cancer). BRCA1/2 mutations confer a lifetime risk of ~70% for breast cancer and ~40% for ovarian cancer. ## Management Strategy for BRCA1 Carriers with Established Cancer **Key Point:** Once a BRCA1 mutation is confirmed in a patient with cancer, the standard of care includes: 1. Completion of cancer treatment (chemotherapy/surgery for current malignancy) 2. Risk-reducing bilateral salpingo-oophorectomy (RRSO) — typically after age 40 or completion of childbearing 3. Risk-reducing bilateral mastectomy (RRM) — offered as an option, especially with bilateral disease **High-Yield:** RRSO is particularly important because: - Reduces ovarian cancer risk by ~80% - Reduces breast cancer risk by ~50% (via estrogen deprivation) if performed premenopausally - Eliminates need for intensive ovarian cancer surveillance ## Why This Patient Needs Bilateral Procedures | Procedure | Indication | Risk Reduction | |-----------|-----------|----------------| | RRSO | BRCA1+ status + completed childbearing | Ovarian cancer ~80%, breast cancer ~50% | | RRM | Bilateral breast cancer + BRCA1+ | Contralateral breast cancer risk ~40% lifetime | **Clinical Pearl:** The sequence is: complete active cancer treatment → offer genetic counseling and discuss options → proceed with risk-reducing surgery. Both procedures are offered, though RRSO is more strongly recommended due to higher ovarian cancer mortality. **Mnemonic:** BRCA-RRSO = **B**RCA carriers need **R**isk-**R**educing **S**alpingo-**O**ophorectomy (and consider RRM for bilateral disease). [cite:Robbins 10e Ch 7]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.